Founded in 2006 as a wholly-owned subsidiary of Pony Biomedicine Group, Pony Biomedicine Laboratory has a total area of nearly 38,000 square meters in Shanghai and Beijing R&D laboratories and covers an area of 60 acres in Hubei GMP API production base. Pony Biomedicine Laboratory is a comprehensive technology platform integrating drug design, drug synthesis, process development, GMP API production, preparation research, TCM resource evaluation, TCM innovative drug development, TCM classic prescription and eponymous prescription development, pharmacodynamic evaluation, pharmacokinetic evaluation, toxicology evaluation and new drug registration. It has CMA and CNAS qualifications. It is implemented in accordance with GMP and GLP, and has been recognized by domestic and international drug administration departments.

The core R&D personnel of Pony Biomedicine are overseas returnees with many years of research and development experience of large international pharmaceutical companies and CRO, and senior professionals in the field of domestic drug research and development. Rich research and development and industrialization have been accumulated in the fields of multi-chiral central drugs and multi-step drug synthesis, slow and controlled release of drug preparations, liposome and nano-preparation technology, drug minimal substance analysis, unknown substance analysis, package material compatibility and sealing, research on origin resources of Chinese medicinal materials, development of Chinese new drugs, secondary development of Chinese medicines, pharmacodynamics and pharmacodynamics, and preclinical toxicological safety evaluation Experience. Bini Biomedical Laboratory focuses on the key technologies of innovative drug research and development, high-end generic drugs, Chinese medicine and ethnic medicine overall research and development, and maintains good cooperative relations with many well-known pharmaceutical enterprises at home and abroad, providing customers with one-stop solutions for biomedical research and development.

Founded in 2002, the group is headquartered in Beijing, and has now developed into a large-scale comprehensive testing group with more than 6000 employees, 30 large-scale experimental bases and more than 100 wholly-owned subsidiaries and branches throughout the country. The group has been recognized as a state-level enterprise technology center, a listed post-doctoral research workstation in Beijing, and a biomedical engineering laboratory approved by Beijing. On September 16, 2020, Pony Testing Group was successfully listed on the Shenzhen Stock Exchange with the stock code 300887.